111 Reports 23.9% Year-Over-Year Revenue Increase of CNY 3696.8 Million for FY2023 Q1
June 29, 2023
☀️Earnings Overview
At the close of Fiscal Year 2023 Q1 on March 31, 2023, 111 ($NASDAQ:YI) reported total revenue of CNY 3696.8 million, an increase of 23.9% from the same time the previous year. Net income for the quarter was CNY -31.8 million, a remarkable improvement when compared to the negative -110.3 million recorded in the first quarter of FY2022.
Analysis
GoodWhale has evaluated 111‘s financial and business fundamentals, and assigned it a Risk Rating of medium. This is based on an analysis of the balance sheet and cashflow statement. Two risk warnings have been detected during this analysis, and to access further details on these warnings, users should register with GoodWhale. 111 has a strong cash position, with a positive free cash flow and enough liquidity to cover its short-term obligations. It also has a healthy financial structure, with little debt and a good balance between assets and liabilities. Overall, 111 is a medium risk investment, but investors should be aware of the two risk warnings that have been flagged up by GoodWhale. By registering with us, they can get access to more information and gain a better understanding of the potential risks involved before making any decisions. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 111. More…
| Total Revenues | Net Income | Net Margin |
| 14.23k | -338.32 | -2.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 111. More…
| Operations | Investing | Financing |
| -76.24 | -123.22 | 65.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 111. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.24k | 2.59k | -5.04 |
Key Ratios Snapshot
Some of the financial key ratios for 111 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 42.9% | – | -2.0% |
| FCF Margin | ROE | ROA |
| -0.8% | 41.8% | -5.4% |
Peers
The company has a strong presence in the Chinese healthcare market and competes with other leading players such as China Jo-Jo Drugstores Inc, Health Advance Inc and Zur Rose Group AG. These companies are all well established providers of healthcare services, offering their respective customers a variety of products and services to choose from.
– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)
China Jo-Jo Drugstores Inc is a leading Chinese national retail drugstore chain that was founded in 2002. It is one of the largest retail drugstore chains in China, with more than 2,000 stores and sales outlets in over 200 cities across the country. As of 2022, the company has a market capitalization of 33.72M. Its Return on Equity (ROE) stands at -4.61%, indicating that the company is not generating a positive return on its shareholders’ investments. Despite this, China Jo-Jo Drugstores Inc’s strong presence in the Chinese market and its aggressive expansion plans make it an attractive investment option.
– Health Advance Inc ($OTCPK:HADV)
Health Advance Inc is a healthcare provider specializing in providing comprehensive and quality care to its patients. The company’s market capitalization stands at 984.94k as of 2022, which reflects its growth and stability in the industry. Its Return on Equity (ROE) of 57.91% is indicative of the company’s efficient use of its assets and capital to generate profits. Health Advance Inc’s impressive market cap and ROE are a testament to its continued success in providing quality care to its patients.
– Zur Rose Group AG ($LTS:0RRB)
Zur Rose Group AG is a Swiss e-commerce and mail-order pharmacy, providing customers with prescription and non-prescription medications, health and beauty products, and medical products. As of 2022, the company has a market capitalization of 357.78 million Swiss francs, indicating its value on the stock market. Furthermore, Zur Rose Group AG has a negative return on equity (ROE) of -29.55%, which is below average, indicating that the company’s management is not efficiently utilizing its shareholders’ equity to generate profits.
Summary
Investors may find 111 Inc a lucrative long-term investment opportunity, as the company reported total revenue of CNY 3696.8 million for the first quarter of FY2023, a 23.9% year-over-year increase. Its net income also showed marked improvement compared to the previous year, dropping from -110.3 million to -31.8 million. 111 Inc’s strong financials indicate impressive growth in the past year, and make it a potentially attractive pick for investors looking for long-term returns.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
